SCHEMBL7124023

SCHEMBL7124023

Nc1cccc(Oc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.45
MMP7 P09237 1/20 0.45
MMP9 P14780 1/20 0.45
MMP13 P45452 1/20 0.45
NPC1 O15118 1/20 0.43
EZH2 Q15910 2/20 0.42
PKM P14618 1/20 0.41
MAOB P27338 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 1/20 0.38
ST14 Q9Y5Y6 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
KCNH2 Q12809 2/20 0.37
TNKS O95271 1/20 0.37
PARP15 Q460N3 1/20 0.37
PARP14 Q460N5 1/20 0.37
PARP10 Q53GL7 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37
PARP2 Q9UGN5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7124170 0.89 MMP2 (0.44) MMP2MMP7MMP9MMP13EZH2
SCHEMBL7125268 0.88 PARP10 (0.53) MMP2MMP7MMP9MMP13NPC1
SCHEMBL7124896 0.88 MMP2 (0.57) MMP2MMP7MMP9MMP13NPC1
SCHEMBL7126701 0.87 PGR (0.48) MMP2MMP7MMP9MMP13NPC1
SCHEMBL7127654 0.87 GRM5 (0.47) MMP2MMP7MMP9MMP13NPC1
SCHEMBL7114486 0.87 KCNH2 (0.48) MMP2MMP7MMP9MMP13NPC1
SCHEMBL7127416 0.86 NPC1 (0.47) MMP2MMP7MMP9MMP13NPC1
SCHEMBL7127363 0.86 MEN1 (0.44) MMP2MMP7MMP9MMP13NPC1
SCHEMBL7116942 0.85 MMP2 (0.43) MMP2MMP7MMP9MMP13NPC1
SCHEMBL7121133 0.85 SLC6A2 (0.47) MMP2MMP7MMP9MMP13NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 MMP2 3731/4885MMP7 2061/4885MMP9 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.